Cited 0 times in
Phase II study of cisplatin with irinotecan as induction chemotherapy followed by chemoradiotherapy for unresectable stage III non-small cell lung cancer
DC Field | Value | Language |
---|---|---|
dc.contributor.author | 김혜련 | - |
dc.contributor.author | 윤상현 | - |
dc.contributor.author | 이창걸 | - |
dc.contributor.author | 장현 | - |
dc.contributor.author | 조병철 | - |
dc.contributor.author | 김세현 | - |
dc.contributor.author | 김주항 | - |
dc.date.accessioned | 2014-12-19T16:27:43Z | - |
dc.date.available | 2014-12-19T16:27:43Z | - |
dc.date.issued | 2012 | - |
dc.identifier.issn | 0250-7005 | - |
dc.identifier.uri | https://ir.ymlib.yonsei.ac.kr/handle/22282913/89571 | - |
dc.description.abstract | BACKGROUND/AIM: We evaluated the anti-tumor activity and safety of cisplatin with irinotecan (IP) induction chemotherapy followed by chemoradiotherapy with etoposide/cisplatin (EP). PATIENTS AND METHODS: Induction chemotherapy consisted of irinotecan i.v. and cisplatin i.v. and was administered on day 1 and day 8 of each cycle. Patients underwent two cycles of chemotherapy with a 3-week interval. In the absence of progressive disease, 66 Gy radiation was administered concurrently with etoposide on days 1 to 5 and 29 to 33, as well as with cisplatin on day 1, 8, 29, and 36. RESULTS: Twenty patients were enrolled between July 2007 and December 2009. This study was closed prematurely due to lack of efficacy in induction chemotherapy. The overall response rate was 45% [95% confidence interval (CI), 25 to 65%], which did not meet the upper limit for first stage rejection of the treatment. The rates of 3-year progression-free survival and overall survival were 17.1% (95% CI, 0 to 36.8%) and 25% (95% CI, 0.2 to 49.8%), respectively. The primary toxicities included neutropenia, diarrhea and fatigue. CONCLUSION: This study failed to demonstrate a benefit for induction chemotherapy which was characterized by suboptimal antitumor activity and was poorly tolerated, with excess treatment-related toxicity. | - |
dc.description.statementOfResponsibility | open | - |
dc.relation.isPartOf | ANTICANCER RESEARCH | - |
dc.rights | CC BY-NC-ND 2.0 KR | - |
dc.rights.uri | https://creativecommons.org/licenses/by-nc-nd/2.0/kr/ | - |
dc.subject.MESH | Aged | - |
dc.subject.MESH | Antineoplastic Combined Chemotherapy Protocols/adverse effects | - |
dc.subject.MESH | Antineoplastic Combined Chemotherapy Protocols/therapeutic use* | - |
dc.subject.MESH | Camptothecin/administration & dosage | - |
dc.subject.MESH | Camptothecin/analogs & derivatives | - |
dc.subject.MESH | Carcinoma, Non-Small-Cell Lung/drug therapy* | - |
dc.subject.MESH | Carcinoma, Non-Small-Cell Lung/pathology | - |
dc.subject.MESH | Carcinoma, Non-Small-Cell Lung/radiotherapy | - |
dc.subject.MESH | Cisplatin/administration & dosage | - |
dc.subject.MESH | Combined Modality Therapy | - |
dc.subject.MESH | Disease Progression | - |
dc.subject.MESH | Female | - |
dc.subject.MESH | Humans | - |
dc.subject.MESH | Lung Neoplasms/drug therapy* | - |
dc.subject.MESH | Lung Neoplasms/pathology | - |
dc.subject.MESH | Lung Neoplasms/radiotherapy | - |
dc.subject.MESH | Male | - |
dc.subject.MESH | Middle Aged | - |
dc.subject.MESH | Neoplasm Staging | - |
dc.title | Phase II study of cisplatin with irinotecan as induction chemotherapy followed by chemoradiotherapy for unresectable stage III non-small cell lung cancer | - |
dc.type | Article | - |
dc.contributor.college | College of Medicine (의과대학) | - |
dc.contributor.department | Dept. of Internal Medicine (내과학) | - |
dc.contributor.googleauthor | HYUN CHANG | - |
dc.contributor.googleauthor | SE HYUN KIM | - |
dc.contributor.googleauthor | BYOUNG CHUL CHO | - |
dc.contributor.googleauthor | SANG HYUN YOON | - |
dc.contributor.googleauthor | HYE RYUN KIM | - |
dc.contributor.googleauthor | CHANG GEOL LEE | - |
dc.contributor.googleauthor | JOO HANG KIM | - |
dc.identifier.doi | 22843939 | - |
dc.admin.author | false | - |
dc.admin.mapping | false | - |
dc.contributor.localId | A01166 | - |
dc.contributor.localId | A02561 | - |
dc.contributor.localId | A03240 | - |
dc.contributor.localId | A03491 | - |
dc.contributor.localId | A03822 | - |
dc.contributor.localId | A00607 | - |
dc.contributor.localId | A00945 | - |
dc.relation.journalcode | J00188 | - |
dc.identifier.eissn | 1791-7530 | - |
dc.identifier.pmid | 22843939 | - |
dc.identifier.url | http://ar.iiarjournals.org/content/32/8/3515.long | - |
dc.subject.keyword | Aged | - |
dc.subject.keyword | Antineoplastic Combined Chemotherapy Protocols/adverse effects | - |
dc.subject.keyword | Antineoplastic Combined Chemotherapy Protocols/therapeutic use* | - |
dc.subject.keyword | Camptothecin/administration & dosage | - |
dc.subject.keyword | Camptothecin/analogs & derivatives | - |
dc.subject.keyword | Carcinoma, Non-Small-Cell Lung/drug therapy* | - |
dc.subject.keyword | Carcinoma, Non-Small-Cell Lung/pathology | - |
dc.subject.keyword | Carcinoma, Non-Small-Cell Lung/radiotherapy | - |
dc.subject.keyword | Cisplatin/administration & dosage | - |
dc.subject.keyword | Combined Modality Therapy | - |
dc.subject.keyword | Disease Progression | - |
dc.subject.keyword | Female | - |
dc.subject.keyword | Humans | - |
dc.subject.keyword | Lung Neoplasms/drug therapy* | - |
dc.subject.keyword | Lung Neoplasms/pathology | - |
dc.subject.keyword | Lung Neoplasms/radiotherapy | - |
dc.subject.keyword | Male | - |
dc.subject.keyword | Middle Aged | - |
dc.subject.keyword | Neoplasm Staging | - |
dc.contributor.alternativeName | Kim, Hye Ryun | - |
dc.contributor.alternativeName | Yoon, Sang Hyun | - |
dc.contributor.alternativeName | Lee, Chang Geol | - |
dc.contributor.alternativeName | Chang, Hyun | - |
dc.contributor.alternativeName | Cho, Byoung Chul | - |
dc.contributor.alternativeName | Kim, Se Hyun | - |
dc.contributor.alternativeName | Kim, Joo Hang | - |
dc.contributor.affiliatedAuthor | Kim, Hye Ryun | - |
dc.contributor.affiliatedAuthor | Yoon, Sang Hyun | - |
dc.contributor.affiliatedAuthor | Lee, Chang Geol | - |
dc.contributor.affiliatedAuthor | Chang, Hyun | - |
dc.contributor.affiliatedAuthor | Cho, Byoung Chul | - |
dc.contributor.affiliatedAuthor | Kim, Se Hyun | - |
dc.contributor.affiliatedAuthor | Kim, Joo Hang | - |
dc.citation.volume | 32 | - |
dc.citation.number | 8 | - |
dc.citation.startPage | 3515 | - |
dc.citation.endPage | 3521 | - |
dc.identifier.bibliographicCitation | ANTICANCER RESEARCH, Vol.32(8) : 3515-3521, 2012 | - |
dc.identifier.rimsid | 32322 | - |
dc.type.rims | ART | - |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.